Enhertu Cancer Associated Fibroblasts 1 000 000 Cells Equipment & Supplies
1 equipment items found
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the ...